Abstract:AIM: To observe the effect of endothelin receptor A activated by endothelin-1 (ET-1) on the expression of cyclooxygenase-2 (COX-2) in atherosclerotic plaque in rabbits. METHODS: The experiment was performed in the Research Center of Xinhua Hospital affiliated to Medical College of Shanghai Jiao Tong University from March to September 2006. ①Thirty-two male New Zealand White Rabbits were randomly divided into baseline group, model group, BQ-123 treatment group, and Simvastatin group with 8 rabbits in each group. ②Sixteen rabbits were fed with standard diet (baseline group) or with high-fat diet containing 1% cholesterol, 10% egg yolk powder, 5% lard and 84% standard forage (model group) for 10 weeks, and the rest sixteen rabbits were fed with high-fat diet for 6 weeks and then intravenously given 4 mL a day selective ETA receptor antagonist BQ-123 (BQ-123 group) or 10 mg/d Simvastatin (Simvastatin group) for another 5 weeks. Fro model group, 4 ml/d normal saline was intravenously injected at 6th week for 5 weeks as negative control. ③After 10 weeks, the peripheral blood of the rabbits was collected from ear artery to determine the levels of total cholesterol (TC), triglyceride (TG), high density lipoprotein cholesterol (HDL-C) and low density lipoprotein cholesterol (LDL-C) in the serum with automatic biochemistry analyzer and the aortas were harvested to detect the expression of endothelin-1, macrophage and cyclooxygenase-2 by SP immunohistochemical staining. RESULTS: Thirty-two rabbits were involved in the result analysis. ①The levels of TC in model group, BQ-123 group and Simvastatin group were significantly higher than that in baseline group (P < 0.01), while the levels of TC in BQ-123 group and Simvastatin group were significantly lower than that in the model group (P < 0.05). ②The levels of TG in model group, BQ-123 group and Simvastatin group were markedly higher than that in the baseline group (P < 0.01). The levels of TG in serum Simvastatin group was markedly lower than that in the model group (P < 0.01), but higher than that in BQ-123 group (P < 0.01). ③The levels of LDL-C in model group, BQ-123 group and Simvastatin group were significantly higher than that in baseline group (P < 0.01). That of the Simvastatin group was lower than that in model group (P < 0.01). ④The levels of HDL-C in serum in the model group, BQ-123 group and Simvastatin group were significantly lower than that in baseline group (P < 0.01). The level of HDL-C in BQ-123 group was higher than that in model group (P < 0.01). ⑤Compared with the model group, the positive expression of ET-1, macrophage-derived foam cells and COX-2 protein in BQ-123 group and Simvastatin group was decreased obviously, especially in BQ-123 group. CONCLUSION: Endothelin receptor A activated by ET-1 significantly up-regulates the expression of COX-2 protein in atherosclerotic plaque, and selective endothelin receptor A antagonist can effectively inhibit the development of atherosclerosis in rabbits.

Cyclooxygenase and atherosclerotic plaque vulnerability

Cyclooxygenase-2 expression, prostacyclin production and endothelial protection of high-density lipoprotein.

Cyclo-Oxygenase 2 Up-Regulates the Effect of Multidrug Resistance

Cyclooxygenase-2 in endothelial and vascular smooth muscle cells restrains atherogenesis in hyperlipidemic mice

[The Impact of Selective Cycloxygenase-2 Inhibitor Celexibo on the Formation of Cholesterol Gallstone].

Cyclooxygenase-2 in human pathological disease

Cyclooxygenase-2 promotes tumor growth and suppresses tumor immunity.

Cytokines and atherosclerosis: a comprehensive review of studies in mice

Expression of COX-2 and its role in rat arterial thrombosis

Xiaoyaosan Prevents Atherosclerotic Vulnerable Plaque Formation Through Heat Shock Protein/glucocorticoid Receptor Axis-Mediated Mechanism.

[COX Plays a Pivotal Role in the Progressive Neuronal Loss in Neurodegenerative Diseases].

New Horizons in the Roles and Associations of COX-2 and Novel Natural Inhibitors in Cardiovascular Diseases

The Study of COX-2 Genetic Polymorphisms and Tumor Hereditary Susceptibility

Exploring the Role of COX-2 in Alzheimer's Disease: Potential Therapeutic Implications of COX-2 inhibitors

Involvement of COX-2 in VEGF-induced angiogenesis via P38 and JNK pathways in vascular endothelial cells.

Recent development on COX-2 inhibitors as promising anti-inflammatory agents: The past 10 years

Expression of Cyclooxygenase‐2 Protein in Colon Disease

Interplay Between Oxidative Stress, Cyclooxygenases, and Prostanoids in Cardiovascular Diseases

Progress of the Relationship Between Cyclooxygenase-2 and Breast Cancer

Endothelin-1 and cyclooxygenase-2 expression in rabbit atherosclerotic plaques

Biochemistry of Cyclooxygenase (COX)-2 Inhibitors and Molecular Pathology of COX-2 in Neoplasia